<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003732</url>
  </required_header>
  <id_info>
    <org_study_id>DAN-104864/373</org_study_id>
    <secondary_id>CDR0000066847</secondary_id>
    <secondary_id>DAN-104864-A/373</secondary_id>
    <secondary_id>EU-98052</secondary_id>
    <secondary_id>SB-104864-A/373</secondary_id>
    <secondary_id>SB-104864/373</secondary_id>
    <nct_id>NCT00003732</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer</brief_title>
  <official_title>A Phase I/II Study to Determine the Maximum Tolerated Doses of Oral Topotecan, Carboplatin and Paclitaxel Administered Every 21 Days to Patients With Epithelial Ovarian Cancer Stages IIb, IIc, III and IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of topotecan combined with carboplatin&#xD;
      and paclitaxel in treating patients who have stage II, stage III, or stage IV ovarian cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose, dose-limiting toxicity, and quantitative and&#xD;
           qualitative toxic effects of oral topotecan combined with intravenous carboplatin and&#xD;
           paclitaxel in patients with stage IIB, IIC, III, or IV ovarian epithelial cancer. (phase&#xD;
           I closed to accrual 12/21/00)&#xD;
&#xD;
        -  Evaluate the anti-tumor activity of this regimen in this patient population.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of topotecan.&#xD;
&#xD;
      Patients receive oral topotecan on days 1-5 and paclitaxel IV over 3 hours followed by&#xD;
      carboplatin IV over 30 minutes on day 5. Courses repeat every 21 days for a maximum of 6&#xD;
      courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Phase I: Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum&#xD;
           tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6&#xD;
           patients experience dose-limiting toxicity. (phase I closed to accrual 12/21/00)&#xD;
&#xD;
        -  Phase II: An additional 50 patients receive up to 6 courses of treatment as in phase I&#xD;
           at the MTD.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years and then every 6 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 80 patients (30 in phase I and 50 in phase II) will be accrued&#xD;
      for this study. (phase I closed to accrual 12/21/00)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose and dose-limiting toxicity of topotecan</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxic effects</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Antitumor activity</measure>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage IIB, IIC, III, or IV ovarian epithelial cancer&#xD;
&#xD;
          -  Measurable or evaluable lesion or microscopic residual disease after first surgery&#xD;
             (phase II patients)&#xD;
&#xD;
          -  No brain and/or leptomeningeal metastases by CT scan or MRI unless asymptomatic&#xD;
             without corticosteroid therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
          -  WBC at least 3,500/mm3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN) unless liver&#xD;
             metastases present&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2 times ULN*&#xD;
&#xD;
          -  SGOT no greater than 2 times ULN* NOTE: *No greater than 5 times ULN if liver&#xD;
             metastases present&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic cardiac disease, including clinical congestive heart failure or&#xD;
             arrhythmias requiring treatment&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other malignancy except basal or squamous cell skin cancer or carcinoma in situ of&#xD;
             the cervix&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No complete bowel obstruction or other condition that would affect GI absorption or&#xD;
             motility&#xD;
&#xD;
          -  No concurrent medical condition for which treatment with platinum, taxane, or&#xD;
             camptothecin analogues are contraindicated&#xD;
&#xD;
          -  No other concurrent medical conditions that would preclude study&#xD;
&#xD;
          -  No mental disease&#xD;
&#xD;
          -  No history of allergy to platinum or taxanes, including drugs containing cremophor&#xD;
             (e.g., cyclosporine or vitamin K)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior camptothecin analogue&#xD;
&#xD;
          -  No prior chemotherapy for ovarian cancer&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent hormonal therapy other than estrogen replacement&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days or 5 half-lives since any prior investigational therapy&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No concurrent metoclopramide or cisapride&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Svend Aage Engelholm, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet - Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2002</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>stage IIB ovarian epithelial cancer</keyword>
  <keyword>stage IIC ovarian epithelial cancer</keyword>
  <keyword>stage IIIA ovarian epithelial cancer</keyword>
  <keyword>stage IIIB ovarian epithelial cancer</keyword>
  <keyword>stage IIIC ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

